Use access key #2 to skip to page content.
$6.33 0.04 (0.64%)
7/3/2008 1:00 PM

Halozyme Therapeutics, Inc. (HALO)

CAPS Rating:
**

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

View All Commentary (HALO)

Recs

0

Avatar icemeta (32.50) Submitted: 12/03/07 9:17 PM : Outperform Start Price: $7.46 HALO Score: -1.27

Explosive drug collaboration, $100 million cash, no debt, director just bought 20% of stock, incredible market opportunity, my largest position

Report this Post Replies: 0 | Reply

Featured Broker Partners